Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 1/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.69 |
| ▸ | ATM | Q13315 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1946258 | 0.88 | L3MBTL1 (0.86) | KDM4EL3MBTL1ATMALDH1A1SMN1; SMN2 | |
| Bromide SCHEMBL10462008 | 0.87 | L3MBTL1 (0.84) | KDM4EL3MBTL1ATMALDH1A1SMN1; SMN2 | |
| SCHEMBL10016602 | 0.84 | KDM4E (1.00) | KDM4EL3MBTL1ATMMEN1KMT2A | |
| SCHEMBL17048438 | 0.83 | CCR8 (0.69) | CCR8KDM4EMEN1KMT2AALDH1A1 | |
| Cadaverine Tartrate SCHEMBL27494555 | 0.82 | L3MBTL1 (0.76) | KDM4EL3MBTL1ATMALDH1A1SMN1; SMN2 | |
| SCHEMBL14022760 | 0.81 | L3MBTL1 (0.74) | CCR8KDM4EL3MBTL1ATMALDH1A1 | |
| SCHEMBL8263564 | 0.81 | L3MBTL1 (0.74) | CCR8KDM4EL3MBTL1ATMALDH1A1 | |
| SCHEMBL1545229 | 0.81 | L3MBTL1 (0.74) | CCR8KDM4EL3MBTL1ATMALDH1A1 | |
| SCHEMBL17048422 | 0.80 | CCR8 (0.66) | CCR8KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL15634802 | 0.80 | CCR8 (0.68) | CCR8KDM4EMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
| WO-2003037271-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS,INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | CCR8 1/4885KDM4E 4617/4885L3MBTL1 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.